IL37 and myeloid sarcoma: Moreover, a significantly higher proportion of samples with dosable circulating IL37 was detected comparing MS patients treated with fingolimod with patients treated with platform therapy (66.66% vs. 0%; p = 0.0001) and with patients untreated (66.66% vs. 0%; p = 0.0001).